| Literature DB >> 31381905 |
Clive Badman1, Charles L Cooney2, Alastair Florence3, Konstantin Konstantinov4, Markus Krumme5, Salvatore Mascia6, Moheb Nasr7, Bernhardt L Trout8.
Abstract
We make the case for why continuous pharmaceutical manufacturing is essential, what the barriers are, and how to overcome them. To overcome them, government action is needed in terms of tax incentives or regulatory incentives that affect time.Keywords: PAT; advanced manufacturing; continuous manufacturing; model-based control; personalized medicine; quality; regulatory incentives; stock-outs; stockpiles; tax incentives
Year: 2019 PMID: 31381905 DOI: 10.1016/j.xphs.2019.07.016
Source DB: PubMed Journal: J Pharm Sci ISSN: 0022-3549 Impact factor: 3.534